According to a recent report by Bloomberg, thousands of people have expressed interest in receiving brain implants from Neuralink, the startup founded by Elon Musk. The company aims to operate on 11 people next year and over 22,000 by 2030. Earlier this year, Neuralink received FDA approval to launch human trials for its device, which Musk has described as a “Fitbit in your skull.” The FDA had previously rejected the company’s bid for human testing due to safety concerns. In September, Neuralink began recruiting for its first human trial, looking for people with paralysis in all four limbs. The company hopes to eventually create a device that allows people to send messages or play games using only their thoughts. However, despite the interest from thousands of prospective patients, Neuralink is still searching for its first volunteer. The surgery involves removing a portion of the skull and inserting a series of electrodes and thin wires into the brain. The company has performed 155 implantation surgeries on animals, but Musk wants the process to be faster and performed without human help. Neuralink faces competition from other brain-computer startups like Synchron and Onward, which have already begun human trials. Musk has emphasized the need for urgency to keep up with AI advancements and the potential risks they pose. However, a Neuralink executive has cautioned against rushing the process.
Related Posts
AAP’s Sanjay Singh Faces Chargesheet in Delhi Liquor Policy Case
- admin
- December 2, 2023
- 1
The Enforcement Directorate has filed a 60-page chargesheet against AAP MP Sanjay Singh in relation to the Delhi excise policy-linked money laundering case. The chargesheet […]
Billionaire Steven Cohen Reveals His Top High Dividend Stock Picks
- admin
- November 21, 2023
- 0
Billionaire Steve Cohen, Chairman and CEO of Point72 Asset Management, is known for his successful investment strategies and shrewdness in the hedge fund industry. With […]
Appeals court will not delay Donald Trump civil fraud trial
- admin
- September 28, 2023
- 0
NEW YORK (Reuters) -A New York appeals court on Thursday refused to delay Donald Trump’s scheduled Oct. 2 civil fraud trial, after the former U.S. […]
